Reshape Raises $20M in Series A Funding

Reshape Raises $20M in Series A Funding

Danish labtech startup Reshaping has successfully raised $20 million in a Series A funding round led by Astanor Ventures and saw participation from notable investors such as Y Combinator, R7, ACME, 21stBio, and Unity co-founder Nicholas Francis.

The newly raised funds will primarily support Reshape's expansion into the United States market and help attract top talent to further expand their offerings.

Reshape Biotech specializes in developing a new generation of lab automation robots as well as infrastructure to increase the efficiency and productivity of scientists and technicians. They aim to leverage automation and digitization to speed up experimental processes and facilitate cross-disciplinary collaboration on a global scale.

The company's robots incorporate advanced technologies such as mechatronics, cloud computing, machine learning-based data analysis, and a deep understanding of biotech applications. These vertically integrated robots streamline data capture and analysis, eliminate redundant processes and enable users to easily digitize microbiology experiments.

Reshape's technology transforms the traditionally slow and error-prone bioassay process into an accurate and scalable operation. By automating manual tasks, their solutions save customers more than 500,000 hours annually, allowing researchers to focus more on innovation and discovery.

According to Carl Emil Gruen, CEO and co-founder of ReShape, funding is not only about improving efficiency, but also about accelerating scientific progress to effectively address global challenges. .

About the Author

Leave a Reply